Bluejay Diagnostics

Bluejay Diagnostics Operating Cash Flow

The Operating Cash Flow of Bluejay Diagnostics (BJDX) as of Nov 3, 2026 is -6.05 M USD. In the previous year, Operating Cash Flow was -7.82 M USD — a change of -22.59% (higher).

Operating Cash Flow

-6.05 MUSD

YoY

-22.59%

Last updated:

Operating Cash Flow of Bluejay Diagnostics is 2025 -6.05 M USD. Operating Cash Flow of Bluejay Diagnostics was 2024 -7.82 M USD. It decreases by -22.59% higher compared to the previous year.

The Bluejay Diagnostics Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-1.69 M USD
Jan 1, 2020
-508,710.00 USD
Jan 1, 2021
-4.37 M USD
Jan 1, 2022
-7.74 M USD
Jan 1, 2023
-8.31 M USD
Jan 1, 2024
-7.82 M USD
Jan 1, 2025
-6.05 M USD
The Bluejay Diagnostics Operating Cash Flow history
YEAROperating Cash FlowYoY
-6.05 MUSD-22.59%
-7.82 MUSD-5.94%
-8.31 MUSD+7.39%
-7.74 MUSD+77.28%
-4.37 MUSD+758.40%
-508,710.00USD-69.90%
-1.69 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bluejay Diagnostics Stock analysis

What does Bluejay Diagnostics do? Bluejay Diagnostics Inc generates revenue through its Symphony System, a near-patient testing platform for disease triage and monitoring. The company's first product, the Symphony IL-6 test, provides rapid sepsis diagnostics with results in about 20 minutes, targeting healthcare providers in acute care settings. The Symphony platform processes whole blood to measure key biomarkers, leveraging non-contact centrifugal force for biomarker isolation and immunoassay preparation. This solution addresses the in vitro diagnostics market segment focused on sepsis, cardio-metabolic diseases, and cancer diagnostics. The Symphony System and its initial IL-6 test are designed for medical professionals seeking faster diagnostic decisions in critical care scenarios. Bluejay Diagnostics targets hospitals and clinics requiring rapid biomarker measurements for patient triage and treatment adjustments. The company's focus on near-patient testing differentiates its offerings within the in vitro diagnostics industry, emphasizing speed and accuracy for time-sensitive conditions. Bluejay Diagnostics Inc operates within the health care equipment and supplies sector, with its Symphony platform positioned to serve the global in vitro diagnostics devices market. The company's initial product, the Symphony IL-6 test for sepsis triage, represents a targeted solution for acute medical conditions requiring immediate diagnostic insights. The Symphony analyzer's ability to process whole blood for biomarker measurement supports its application in multiple disease areas including sepsis and cardio-metabolic conditions. Bluejay Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bluejay Diagnostics stock

Operating Cash Flow of Bluejay Diagnostics is -6.05 M USD in 2025.

Operating Cash Flow of Bluejay Diagnostics changed from -7.82 M USD to -6.05 M USD, representing a -22.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Bluejay Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Bluejay Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bluejay Diagnostics

All Key Metrics — Bluejay Diagnostics